Effects of long-term administration of low-dose lactitol in patients with cirrhosis but without overt encephalopathy

Francesco Salerno, Pamela Moser, Alessandra Maggi, Giovanna Vitaliani, Gianpiero Benetti

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

To investigate the efficacy and the acceptability of different doses of lactitol in patients with subclinical hepatic encephalopathy, 28 patients with cirrhosis were enrolled in a controlled clinical trial comparing 5-month therapies with lactitol at two different doses: 0.3 and 0.5 g/kg bw per day. This period was followed by 1 month of recovery. Patients were monitored with venous blood ammonia determination, three psychometric tests, clinical evaluation of mental status and EEG. The porto-systemic encephalopathy index of Conn was determined periodically. Twenty-two patients completed the trial (11 for each dose of lactitol). Both doses of lactitol decreased plasma ammonia levels and improved the porto-systemic encephalopathy index. The higher dose was more effective in improving performance in the psychometric tests. After the period of recovery, both the porto-systemic encephalopathy index and the psychometric test scores returned to pretreatment values. Lactitol was tolerated well by patients. Three patients given the higher dose reported periodic intestinal discomfort, but did not stop taking lactitol or reduce the dosage; no side-effects were reported by the patients taking the lower dose. These results indicate that lactitol in doses ranging from 0.3 to 0.5 g/kg bw is a well-tolerated and effective treatment for subclinical encephalopathy.

Original languageEnglish
Pages (from-to)1092-1096
Number of pages5
JournalJournal of Hepatology
Volume21
Issue number6
DOIs
Publication statusPublished - 1994

Fingerprint

Brain Diseases
Fibrosis
Psychometrics
Ammonia
Hepatic Encephalopathy
Controlled Clinical Trials
lactitol
Electroencephalography
Therapeutics

Keywords

  • Ammonia
  • Cirrhosis
  • Encephalopathy
  • Lactitol
  • Psychometric tests

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Effects of long-term administration of low-dose lactitol in patients with cirrhosis but without overt encephalopathy. / Salerno, Francesco; Moser, Pamela; Maggi, Alessandra; Vitaliani, Giovanna; Benetti, Gianpiero.

In: Journal of Hepatology, Vol. 21, No. 6, 1994, p. 1092-1096.

Research output: Contribution to journalArticle

Salerno, Francesco ; Moser, Pamela ; Maggi, Alessandra ; Vitaliani, Giovanna ; Benetti, Gianpiero. / Effects of long-term administration of low-dose lactitol in patients with cirrhosis but without overt encephalopathy. In: Journal of Hepatology. 1994 ; Vol. 21, No. 6. pp. 1092-1096.
@article{cddcf7adfb1243368530c80aacc29251,
title = "Effects of long-term administration of low-dose lactitol in patients with cirrhosis but without overt encephalopathy",
abstract = "To investigate the efficacy and the acceptability of different doses of lactitol in patients with subclinical hepatic encephalopathy, 28 patients with cirrhosis were enrolled in a controlled clinical trial comparing 5-month therapies with lactitol at two different doses: 0.3 and 0.5 g/kg bw per day. This period was followed by 1 month of recovery. Patients were monitored with venous blood ammonia determination, three psychometric tests, clinical evaluation of mental status and EEG. The porto-systemic encephalopathy index of Conn was determined periodically. Twenty-two patients completed the trial (11 for each dose of lactitol). Both doses of lactitol decreased plasma ammonia levels and improved the porto-systemic encephalopathy index. The higher dose was more effective in improving performance in the psychometric tests. After the period of recovery, both the porto-systemic encephalopathy index and the psychometric test scores returned to pretreatment values. Lactitol was tolerated well by patients. Three patients given the higher dose reported periodic intestinal discomfort, but did not stop taking lactitol or reduce the dosage; no side-effects were reported by the patients taking the lower dose. These results indicate that lactitol in doses ranging from 0.3 to 0.5 g/kg bw is a well-tolerated and effective treatment for subclinical encephalopathy.",
keywords = "Ammonia, Cirrhosis, Encephalopathy, Lactitol, Psychometric tests",
author = "Francesco Salerno and Pamela Moser and Alessandra Maggi and Giovanna Vitaliani and Gianpiero Benetti",
year = "1994",
doi = "10.1016/S0168-8278(05)80623-3",
language = "English",
volume = "21",
pages = "1092--1096",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier B.V.",
number = "6",

}

TY - JOUR

T1 - Effects of long-term administration of low-dose lactitol in patients with cirrhosis but without overt encephalopathy

AU - Salerno, Francesco

AU - Moser, Pamela

AU - Maggi, Alessandra

AU - Vitaliani, Giovanna

AU - Benetti, Gianpiero

PY - 1994

Y1 - 1994

N2 - To investigate the efficacy and the acceptability of different doses of lactitol in patients with subclinical hepatic encephalopathy, 28 patients with cirrhosis were enrolled in a controlled clinical trial comparing 5-month therapies with lactitol at two different doses: 0.3 and 0.5 g/kg bw per day. This period was followed by 1 month of recovery. Patients were monitored with venous blood ammonia determination, three psychometric tests, clinical evaluation of mental status and EEG. The porto-systemic encephalopathy index of Conn was determined periodically. Twenty-two patients completed the trial (11 for each dose of lactitol). Both doses of lactitol decreased plasma ammonia levels and improved the porto-systemic encephalopathy index. The higher dose was more effective in improving performance in the psychometric tests. After the period of recovery, both the porto-systemic encephalopathy index and the psychometric test scores returned to pretreatment values. Lactitol was tolerated well by patients. Three patients given the higher dose reported periodic intestinal discomfort, but did not stop taking lactitol or reduce the dosage; no side-effects were reported by the patients taking the lower dose. These results indicate that lactitol in doses ranging from 0.3 to 0.5 g/kg bw is a well-tolerated and effective treatment for subclinical encephalopathy.

AB - To investigate the efficacy and the acceptability of different doses of lactitol in patients with subclinical hepatic encephalopathy, 28 patients with cirrhosis were enrolled in a controlled clinical trial comparing 5-month therapies with lactitol at two different doses: 0.3 and 0.5 g/kg bw per day. This period was followed by 1 month of recovery. Patients were monitored with venous blood ammonia determination, three psychometric tests, clinical evaluation of mental status and EEG. The porto-systemic encephalopathy index of Conn was determined periodically. Twenty-two patients completed the trial (11 for each dose of lactitol). Both doses of lactitol decreased plasma ammonia levels and improved the porto-systemic encephalopathy index. The higher dose was more effective in improving performance in the psychometric tests. After the period of recovery, both the porto-systemic encephalopathy index and the psychometric test scores returned to pretreatment values. Lactitol was tolerated well by patients. Three patients given the higher dose reported periodic intestinal discomfort, but did not stop taking lactitol or reduce the dosage; no side-effects were reported by the patients taking the lower dose. These results indicate that lactitol in doses ranging from 0.3 to 0.5 g/kg bw is a well-tolerated and effective treatment for subclinical encephalopathy.

KW - Ammonia

KW - Cirrhosis

KW - Encephalopathy

KW - Lactitol

KW - Psychometric tests

UR - http://www.scopus.com/inward/record.url?scp=0028630563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028630563&partnerID=8YFLogxK

U2 - 10.1016/S0168-8278(05)80623-3

DO - 10.1016/S0168-8278(05)80623-3

M3 - Article

C2 - 7699233

AN - SCOPUS:0028630563

VL - 21

SP - 1092

EP - 1096

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 6

ER -